<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Immuno-oncology Targets & Combinations

Leverage comprehensive in vitro, in vivo, ex vivo, and in silico platforms, utilizing immunocompetent, humanized, or patient-derived models. With robust biomarker analysis and a focus on checkpoint inhibitors, you can optimize combination strategies.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Fatty Acid Degradation (FAD) Subtypes of HCC PDX Models Accurately Recapitulate Anti-Cancer Drug Sensitivity in Patients

Liver cancer remains a major health burden in the U.S. and globally, with incidence rates continuing to rise. Estimates indicate that liver cancer will affect more than 1 million individuals annually in coming years. Hepatocellular carcinoma (HCC), the predominant form that accounts for roughly 90% of primary liver cancer cases, is highly complex and heterogeneous and is often associated with underlying chronic liver disease, such as hepatitis.

While HCC treatments have advanced greatly in recent years, the need persists for additional therapeutic options and predictive biomarkers to guide personalized therapy. In this post, we explore a new study that proposes to classify HCC into three subtypes (F1, F2, and F3) based on activity of the fatty acid degradation (FAD) pathway, with each subtype displaying distinct clinical and biological features that could enable improved therapy matching and clinical decision-making. Moreover, the authors used patient-derived xenograft (PDX) models of HCC to validate responder and non-responder profiles of sorafenib that correlate with FAD activity across the three subtypes.

The FAD Pathway is Downregulated in Multiple Cancers and Correlates with Fatty Acid Content in Tumors

It is well-established that cancer cells often divert carbon from energy production to fatty acid production since fatty acids can be used for the biosynthesis of membranes and signaling molecules. Indeed, some cancers depend on blockade of the FAD pathway for survival, with many tumors showing significant downregulation of members of the FAD pathway which are involved in mitochondrial and peroxisomal oxidation. This downregulation prevents fatty acid breakdown via mitochondrial β-oxidation, resulting in accumulation of free fatty acids (FFAs) that cancer cells harness for energy storage, membrane proliferation, and signaling molecule generation. The widespread suppression of FAD pathway genes, and resulting reliance on FFAs, indicates that certain cancer types require inhibition of the FAD pathway to thrive, and thus, a better understanding of the dysregulated FAD pathway in cancers like HCC may reveal new therapeutic strategies and treatment insights.

Identification and Validation of a FAD-based Subtype of HCC and Its Prognostic Correlations

In a collaborative study that included scientists from multiple institutes including Crown Bioscience, RNA sequencing (RNA-seq), PCR-array, lipidomics, metabolomics, and proteomics analyses were conducted on a cohort of human HCC tumors. After validating the downregulation of FAD pathway genes and increased content of FFAs in this cohort, a novel molecular classification termed “F subtype” (F1, F2, and F3) was developed based on a highly comprehensive analysis of the expression profile and prognostic value of the FAD pathway in nine independent datasets that included more than 1,500 patients. Furthermore, the team characterized the clinical, mutational, epigenetic, metabolic, and immunological features of each FAD-based subtype. For instance, from an immunological perspective, F1 subtypes show higher expression of CD8, cytotoxic, and exhausted T cells marker genes compared to F3 subtypes, while F1-derived T cells were identified as progenitor, proliferating, effector-like, and terminally exhausted T cells, whereas all the F3-derived T cells were identified as progenitor.

Overall, in terms of FAD pathway gene expression and overall and relapse-free patient survival times, the F1, F2, and F3 subtypes were characterized as follows:

  • F1 Subtype:
    • Lowest expression of FAD pathway genes
    • Shortest overall and relapse-free survival times
  • F2 Subtype:
    • Moderate expression of FAD pathway genes
    • Moderate overall and relapse-free survival times
  • F3 Subtype:
    • Highest expression of FAD pathway genes
    • Longest overall and relapse-free survival times

In summary, the F1 subtype with the lowest fatty acid degradation pathway gene expression had the worst prognosis, while the F3 subtype with highest FAD gene expression had the best outcomes in terms of overall and relapse-free survival times.

FAD Subtypes Predict Response to HCC Treatment Regimens

Next, the investigators evaluated the association between the FAD subtypes and response to several first-line treatments, including sorafenib, transarterial chemoembolization (TACE), and immune checkpoint inhibitors (ICI).

For patients that received sorafenib, it was found that F1 patients had the highest response rate, while the majority (90%) of F3 patients were non-responders.

For patients who underwent TACE, the F3 patients had the highest response rate, while all patients in the F1 subtype were TACE non-responders.

For ICI response, it was determined that the majority of F1 subtype patients (77.8%) were PD1 responders, which was significantly higher than both the F2 and F3 subtypes. The researchers also evaluated whether FAD subtypes could predict response to anti-PD-L1 monotherapy. It was determined that the F1 subtype patients experienced higher response rates than the other two subtypes, and atezolizumab responders had lower FAD scores than non-responders, indicating FAD subtypes are associated with anti-PD-L1 monotherapy response.

Overall, F1 subtype patients are responsive to sorafenib, anti-PD1, anti-PD-L1, and atezolizumab plus bevacizumab (T+A) treatment, while F3 subtype patients had the highest response to TACE, and F2 subtype patients may be good candidates for T+A combinations.

PDX HCC Models Confirm the Clinical Response

PDX HCC models were used to validate the sorafenib clinical response patterns described above. After classifying the PDX models into their respective FAD subtypes, it was determined that sorafenib treatment showed greater efficacy in F1 and F2 tumors as compared to F3 tumors, mirroring the clinical findings.

This concordance between PDX models and patient outcomes underscores the predictive value of these PDX models for investigating the relationships between FAD activity and treatment response in HCC. Defining predictive biomarkers via PDX evaluation of the FAD-based subtypes represents a promising approach to pave the way for more precise, personalized HCC therapy.

Conclusion

This new study proposes a novel classification of HCC subtypes based on FAD pathway activity, which correlates with prognosis and treatment response in patients. Furthermore, PDX HCC models showed great utility as preclinical tools as they validated the sorafenib responder and non-responder profiles based on FAD activity.

Did You Know? Crown Bioscience has an extensive collection of liver cancer PDX models, including several orthotopic models that closely recapitulate the tumor microenvironment. Crown Bioscience’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions. Check out our extensive collection of liver cancer PDX models here.


Related Posts